RE:RE:RE:RE:RE:Both Roche and Incyte have turned me down as an MSLA closer look at AN. Two drugs appear to be at their forefront. Buparlisib - AN2025. Palupiprant - AN0025.
AN2025 has been in 90 trials or more.
AN2025 and AN0025 and Tecentriq are involved in an interesting Double/Triple that is progressing very nicely. NCT04975958. Fair to assume a strong connection to Roche.
AN0025 and Keytruda are being tested together. So a relationship with Merck.
AN1004 Pelareorep. Phase 3 Bridging Study. Active, not recruiting. Oncolytics Biotech.
Two of the most interesting trials at ONC/Y; GOBLET - Roche. AMBUSH - Merck.
A tangled web, that does not include, and may, BMS and Pfizer, and others.
More to AN than meets the eye.
I still think we will be approached by an entity of two or more.
Just a guess. It could go any number of ways